A differentiated approach to drug treatment of attention deficit hyperactivity disorder in children

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common and complex neurodevelopmental disorder characterized by persistent manifestations of hyperactivity, inattention, and impulsivity, which leads to negative consequences for the quality of life. Aim – to conduct a review of current data of ADHD etiopathogenesis, variants of clinical manifestations, and to study a differentiated approach to the pharmacotherapy of ADHD in children, in particular the advantages of using the NIHT approach to the treatment of ADHD in children. Data on the prevalence, etiology, pathogenesis, variants of the clinical course of ADHD in children, current recommendations and manuals for the diagnosis and treatment of ADHD, in particular first-, second-, and third-line drug treatment, as well as a differentiated approach to the use of adjuvant drugs and alternative approaches to the treatment of ADHD were systematized and analyzed. The possibilities of NIHT approach (Non-Individualised Homeopathic Treatment) in the pharmacotherapy of ADHD in children are considered, particularly the use of the drug Kindinorm® N. Conclusions. A differentiated approach to the drug treatment of ADHD in children should take into account the variants of the clinical course of ADHD, the characteristics and severity of symptoms, the clinical response to the use of "protocol" drugs, their tolerability and compliance with the regimen, as well as the possibilities of the NIHT approach both in complex treatment and in monotherapy.